Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.
Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.
复制标题
依达拉奉对不涉及脑梗塞的神经系统疾病具有神经保护作用的潜力。
DOI：
--
复制
发表时间：
2011
影响因子：
2.7
通讯作者：
M. Shigemori
中科院分区：
文献类型：
--
作者：
K. Kikuchi;K. Kawahara;H. Uchikado;N. Miyagi;T. Kuramoto;T. Miyagi;Y. Morimoto;Takashi Ito;S. Tancharoen;N. Miura;K. Takenouchi;Yoko Oyama;B. Shrestha;F. Matsuda;Y. Yoshida;Shinihiro Arimura;Kentaro Mera;K. Tada;Narimasa Yoshinaga;Ryuichi Maenosono;Yoshiko Ohno;T. Hashiguchi;I. Maruyama;M. Shigemori
依达拉奉最初是作为一种有效的自由基清除剂开发的，自2001年以来在日本被广泛用于治疗脑梗死。几种自由基清除剂已被开发，其中一些已进展到临床试验，用于治疗脑梗死。其中一种清除剂依达拉奉已被日本监管机构批准用于治疗脑梗死患者。特别令人感兴趣的是依达拉奉在各种神经系统疾病中扩散到中枢神经系统的能力。除羟自由基清除作用外，依达拉奉还被发现对炎症、基质金属蛋白酶、一氧化氮产生和凋亡细胞死亡具有有益作用。一致地，已经发现依达拉奉在许多疾病的动物模型中具有神经保护作用，包括中风、脊髓损伤、创伤性脑损伤、神经变性疾病和脑肿瘤。作为自由基清除剂使用9年后，依达拉奉的安全性已得到证实，这表明它可能有潜力发展成为人类多种神经系统疾病的有效治疗药物。
Edaravone was originally developed as a potent free radical scavenger and has been widely used to treat cerebral infarction in Japan since 2001. Several free radical scavengers have been developed and some of them have progressed to clinical trials for the treatment of cerebral infarction. One such scavenger, edaravone, has been approved by the regulatory authority in Japan for the treatment of patients with cerebral infarction. Of particular interest is the ability of edaravone to diffuse into the central nervous system in various neurologic diseases. Aside from its hydroxyl radical scavenging effect, edaravone has been found to have beneficial effects on inflammation, matrix metalloproteinases, nitric oxide production and apoptotic cell death. Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. The proven safety of edaravone following 9 years of use as a free radical scavenger suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.
DOI：
10.1017/cbo9780511544910.012
发表时间：
2002-09
期刊：
The Mount Sinai journal of medicine, New York
影响因子：
--
作者：
M. Papadopoulos;Sanjeev Krishna;A. Verkman
通讯作者：
M. Papadopoulos;Sanjeev Krishna;A. Verkman